Serum copper and ceruloplasmin levels (SCL, SCeL) in 57 patients with advanced cancer of the stomach (35 cases) or large intestine (22 cases) treated with polychemotherapy were studies. In gastroenteric cancer, SCL, which are already high in untreated patients, have a tendency to increase further in cases of progression of the disease, while they seem to significantly decrease in cases of remission. SCeL during the trial appeared to be correlated to the clinical evolution of the disease only in the case of stomach cancer. In large intestine cancer, SCeL did not show any significant variation in relation to the normal range. These observations, in particular on the behavior of SCL in the neoplasms of the digestive tract, are in accordance with the results of other studies. The authors are inclined to attach a diagnostic and prognostic value to the variation in SCL and SCeL in gastrointestinal cancer.
Get full access to this article
View all access options for this article.
References
1.
BreiterD.N., DiasioR.B., NeifeldJ.P., RoushM.L., RosembergS.A.: Serum copper and zinc measurements in patients with osteogenic sarcoma.Cancer, 42: 598–602, 1978.
2.
BonadonnaG., BrusamolinoE., ValagussaP., RossiA., BrugnatelliL., BrambillaC., De LenaM., TanciniG., BajettaE., MusumeciR., VeronesiU.: Combination chemotherapy as an adjuvant treatment in operable breast cancer.N. Engl. J. Med., 249: 405–410, 1976.
3.
BonadonnaG., RossiA., ValagussaP., BanfiA., VeronesiU.: The CMF program for operable breast cancer with positive axillary nodes.Cancer, 39: 2904–2915, 1977.
4.
CassanoC., FiaschiE., AndresG.A.: La sindrome nefrosica. Correlazioni fisiopatologiche ed istopatogenetiche con le glomerulonefriti. Relaz. 61° Congresso Nazionale Soc. It. Medicina Interna. Napoli, ottobre 1960.
5.
De LenaM., BrambillaC., MorabitoA., BonadonnaG.: Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate and 5-fluorouracil for advanced breast cancer.Cancer, 35: 1108–1115, 1975.
6.
FisherG.L., ByersV.S., ShifrineM., LevinA.S.: Copper and zinc levels in serum from human patients with sarcomas.Cancer, 37: 356–363, 1976.
7.
HrgovicM., TessmerC.R., ThomasF.B., FullerM.L., GambleG.F., ShullenbergerC.C.: Significance of serum copper level in adult patients with Hodgkin's disease.Cancer, 31: 1337–1345, 1973.
8.
KolaricK., RoguljicA., FussV.: Serum copper levels in patients with solid tumors.Tumori, 61: 173–177, 1975.
9.
InutsukaS., ArakiS.: Plasma copper and zinc levels in patients with malignant tumors of digestive organs. Clinical evaluation of the Cu/Zn ratio.Cancer, 42: 626–631, 1978.
10.
LivingstoneR.B., FeeW.H., EinhornL.H., BurgessM.A., FreireichE.J., GottliebJ.A., FarberM.O.: BACON (bleomycin, adriamycin, CCNU, oncovin and nitrogen mustard), in squamous lung cancer. Experience in fifty patients.Cancer, 37: 1237–1242, 1976.
11.
MarkowitzH., GublerJ.C., MahoneyG.P., CartwrightG.E., WintrobeM.M.: Studies on copper metabolism. XIV. Copper ceruloplasmin and oxidase activity in sera of normal human subjects, pregnant women, and patients with infection, hepatolenticular degeneration and nephrotic syndrome.J. Clin. Invest., 34: 1498–1508, 1955.
12.
MasiM., VecchiV., VivarelliF., PaolucciP.: La ceroplasminemia nella leucosi acuta linfoblastica e nel morbo di Hodgkin dell'infanzia.Minerva Pediat., 22: 1223–1228, 1975.
13.
MortazaviS.H., Beni-HashemiA., MozafariM., RaffiA.: Value of serum copper measurement in lymphomas and several other malignancies.Cancer, 29: 1193–1198, 1972.
14.
PisiE., Di FeliciantonioR., FigusE., FerriS.: Comportamento e significato prognostico della ceruloplasmina serica in relazione al quadro istopatologico nella malattia di Hodgkin.Minerva Med., 59: 944–952, 1968.
15.
PizzoloG., SavarinT., MolinoA.M., AmbosettiA., TodeschiniG., VettoreL.: The diagnostic value of serum copper levels and other hematochemical parameters in malignancies.Tumori, 64: 55–61, 1978.
16.
PlumC.M., HansenS.E.: Studies on variations in serum copper and in serum copper oxidase activity, together with studies on the copper content of the cerebrospinal fluid, with particular reference to the variations in multiple sclerosis.Acta Psych. Neurol. Scand. Suppl., 148: 41–78, 1960.
17.
ScanniA., LicciardelloL., TrovatoM., TomirottiM., BiraghiM.: Serum copper and ceruloplasmin levels in patients with neoplasias localised in the stomach, large intestine or lung.Tumori, 63: 175–180, 1977.
18.
SearcyR.L.: Copper. pp. 184–192. In: Diagnostic Biochemistry.McGraw-Hill Ed., New York, 1969.
19.
ShifrineM., FisherG.L.: Ceruloplasmin levels in serum from human patients with osteosarcoma.Cancer, 38: 244–248, 1976.
20.
StrainW.H., MansourE.G., FlynnA., PoresW.J., TomaroA.J., HillO.A.: Plasma zinc concentration in patients with broncogenic cancer.Lancet, 1: 1021–1022, 1972.
21.
TessmerC.F., HrgovicM., BrownB.W.: Serum copper correlation with bone marrow.Cancer, 29: 173–197, 1972.
22.
TessmerC.F., HrgovicM., ThomasF.B., FullerL.M., CastroG.R.: Serum copper as an index of tumor response to radiotherapy.Radiology, 106: 635–639, 1973.
23.
ThorlingE.B., ThorlingK.: The clinical usefullness of serum copper determination in Hodgkin's disease.Cancer, 38: 225–231, 1976.
